Neurobiology of Aging
Volume 28, Issue 9 , Pages 1388-1395 , September 2007

Long-term soluble Aβ1–40 activates CaM kinase II in organotypic hippocampal cultures

  • Daniela Tardito

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • ,
  • Massimo Gennarelli

      Affiliations

    • Genetics Unit, IRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
    • ,
  • Laura Musazzi

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • ,
  • Raffaella Gesuete

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • ,
  • Stefania Chiarini

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • ,
  • Valentina Sara Barbiero

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • ,
  • Russell E. Rydel

      Affiliations

    • Elan Pharmaceuticals, South San Francisco, CA, USA
    • Present address: Jiva Bioscences, Inc., Mountain View, CA 94040 USA.
    • ,
  • Giorgio Racagni

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • Genetics Unit, IRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
    • ,
  • Maurizio Popoli

      Affiliations

    • Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 50318361; fax: +39 02 50318278.

Received 19 January 2006 ,Revised 23 May 2006 ,Accepted 12 June 2006.

References 

  1. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci. 2005;25(13):3270–3279
  2. Cavazzin C, Bonvicini C, Nocera A, Racchi M, Kasahara J, Tardito D, et al. Expression and phosphorylation of δ-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiol Aging. 2004;25(8):1187–1196
  3. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001;21(12):4125–4133
  4. Fukunaga K, Stoppini L, Miyamoto E, Muller D. Long-term potentiation is associated with an increased activity of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1993;268:7863–7867
  5. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble amyloid Aβ(1–40) exists as a stable dimer at low concentrations. J Biol Chem. 1997;272(34):21037–21044
  6. Gray CW, Patel AJ. Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Brain Res. 1995;691(1/2):169–179
  7. Griffith LC. Regulation of calcium/calmodulin-dependent protein kinase II activation by intramolecular and intermolecular interactions. J Neurosci. 2004;24(39):8394–8398
  8. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci. 2000;12(8):2735–2745
  9. Harper JD, Wong SS, Lieber CM, Lansbury PT. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 1999;38(28):8972–8980
  10. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001;24(4):219–224
  11. Koh JY, Yang LL, Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990;533(2):315–320
  12. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95(11):6448–6453
  13. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2(3):404–410
  14. Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci. 2002;3(3):175–190
  15. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155(3):853–862
  16. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992;12(2):376–389
  17. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46(6):860–866
  18. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050–4058
  19. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789–791
  20. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci. 2005;8(8):1051–1058
  21. Tartaglia N, Du J, Tyler WJ, Neale E, Pozzo-Miller L, Lu B. Protein synthesis-dependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor. J Biol Chem. 2001;276(40):37585–37593
  22. Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, Vinters HV, et al. Deposition of monomeric, not oligomeric, Aβ mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry. 1999;38(32):10424–10431
  23. Van Uden E, Sagara Y, Van Uden J, Orlando R, Mallory M, Rockenstein E, et al. A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity. J Biol Chem. 2000;275(39):30525–30530
  24. Vitolo OV, Sant’Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signalling. Proc Natl Acad Sci USA. 2002;99(20):13217–13221
  25. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535–539
  26. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci. 2005;25(5):1071–1080
  27. Zhao D, Watson JB, Xie CW. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol. 2004;92(5):2853–2858

PII: S0197-4580(06)00221-1

doi: 10.1016/j.neurobiolaging.2006.06.012

Neurobiology of Aging
Volume 28, Issue 9 , Pages 1388-1395 , September 2007

Article Tools

* Image Usage & Resolution